Translation inhibition by rocaglates is independent of eIF4E phosphorylation status

Molecular Cancer Therapeutics

Volumn 15, Issue 1, 2016, Pages 136-141

  Chu, Jennifer ^a   Cencic, Regina ^a   Wang, Wenyu ^b   Porco, John A ^b   Pelletier, Jerry ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b USA   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INITIATION FACTOR 4E; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NATURAL PRODUCT; ROCAGLATE; UNCLASSIFIED DRUG; BENZOFURAN DERIVATIVE; BIOLOGICAL PRODUCT; CYCLOPENTANE DERIVATIVE;

3T3 CELL LINE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; EMBRYO; ENANTIOMER; IC50; JURKAT CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RNA BINDING; STEREOISOMERISM; WESTERN BLOTTING; ANIMAL; CELL LINE; DRUG EFFECTS; HUMAN; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOFURANS; BIOLOGICAL PRODUCTS; CELL LINE; CYCLOPENTANES; EUKARYOTIC INITIATION FACTOR-4E; HUMANS; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION;

EID: 84958163217     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0409     Document Type: Article

References (34)

1. Ebada SS, Lajkiewicz N, Porco JA Jr, Li-Weber M, Proksch P. Chemistry and biology of rocaglamides (=flavaglines) and related derivatives from aglaia species (meliaceae). Prog Chem Org Nat Prod 2011;94:1-58.
2. Cencic R, Carrier M, Galicia-Vazquez G, Bordeleau ME, Sukarieh R, Bourdeau A, et al. Antitumor activity and mechanism of action of the cyclopenta[ b]benzofuran, silvestrol. PLoS One 2009;4:e5223.
3. Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 2009;113:4656-66.
4. Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, et al. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. J Hematol Oncol 2013;6:21.
5. BordeleauME, Robert F, Gerard B, Lindqvist L, Chen SM, Wendel HG, et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 2008;118:2651-60.
6. Robert F, RomanW, Bramoulle A, Fellmann C, Roulston A, Shustik C, et al. Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma. Proc Natl Acad Sci U S A 2014;111:13421-6.
7. Giaisi M, Kohler R, Fulda S, Krammer PH, Li-WeberM. Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas. Int J Cancer 2012;131:1003-8.
8. Chu J, Pelletier J. Targeting the eIF4A RNA helicase as an anti-neoplastic approach. Biochim Biophys Acta 2015;1849:781-91.
9. Rodrigo CM, Cencic R, Roche SP, Pelletier J, Porco JA. Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies. J Med Chem 2012;55: 558-62.
10. Duncan R, Hershey JW. Identification and quantitation of levels of protein synthesis initiation factors in crude HeLa cell lysates by two-dimensional polyacrylamide gel electrophoresis. J Biol Chem 1983;258:7228-35.
11. Galicia-Vazquez G, Cencic R, Robert F, Agenor AQ, Pelletier J. A cellular response linking eIF4AI activity to eIF4AII transcription. RNA 2012;18: 1373-84.
12. Wolfe AL, Singh K, Zhong Y, Drewe P, Rajasekhar VK, Sanghvi VR, et al.RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature 2014;513:65-70.
13. Rubio CA, Weisburd B, Holderfield M, Arias C, Fang E, DeRisi JL, et al. Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation. Genome Biol 2014;15:476.
14. Liu T, Nair SJ, Lescarbeau A, Belani J, Peluso S, Conley J, et al. Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors. J Med Chem 2012;55:8859-78.
15. Chambers JM, Lindqvist LM, Webb A, Huang DC, Savage GP, Rizzacasa MA. Synthesis of biotinylated episilvestrol: highly selective targeting of the translation factors eIF4AI/II. Org Lett 2013;15:1406-9.
16. Sadlish H, Galicia-Vazquez G, Paris CG, Aust T, Bhullar B, Chang L, et al. Evidence for a functionally relevant rocaglamide binding site on the eIF4ARNA complex. ACS Chem Biol 2013;8:1519-27.
17. Polier G, Neumann J, Thuaud F, Ribeiro N, Gelhaus C, Schmidt H, et al. The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2. Chem Biol 2012;19:1093-104.
18. Rajalingam K, Wunder C, Brinkmann V, Churin Y, Hekman M, Sievers C, et al. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat Cell Biol 2005;7:837-43.
19. Topisirovic I, Ruiz-Gutierrez M, Borden KL. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res 2004;64:8639-42.
20. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007;21:3232-7.
21. Pestova TV, Shatsky IN, Hellen CU. Functional dissection of eukaryotic initiation factor 4F: the 4A subunit and the central domain of the 4G subunit are sufficient to mediate internal entry of 43S preinitiation complexes. Mol Cell Biol 1996;16:6870-8.
22. Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A 2010;107:14134-9.
23. Robichaud N, DelRincon SV, Huor B, Alain T, Petruccelli LA, Hearnden J, et al. Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene 2014;34:2032-42.
24. Ueda T, Sasaki M, Elia AJ, Chio II, Hamada K, Fukunaga R, et al. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci U S A 2010;107:13984-90.
25. Stone SD, Lajkiewicz NJ, Whitesell L, Hilmy A, Porco JA Jr. Biomimetic kinetic resolution: highly enantio-and diastereoselective transfer hydrogenation of aglain ketones to access flavagline natural products. J AmChem Soc 2015;137:525-30.
26. Gerard B, Sangji S, O'Leary DJ, Porco JA Jr. Enantioselective photocycloaddition mediated by chiral Bronsted acids: asymmetric synthesis of the rocaglamides. J Am Chem Soc 2006;128:7754-5.
27. Gerard B, Cencic R, Pelletier J, Porco JA Jr. Enantioselective synthesis of the complex rocaglate (-)-silvestrol. Angew Chem Int Ed Engl 2007;46: 7831-4.
28. Cencic R, Galicia-Vazquez G, Pelletier J. Inhibitors of translation targeting eukaryotic translation initiation factor 4A. Methods Enzymol 2012;511: 437-61.
29. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 2004;24:6539-49.
30. Tschopp C, Knauf U, Brauchle M, Zurini M, Ramage P, Glueck D, et al. Phosphorylation of eIF-4E on Ser 209 in response to mitogenic and inflammatory stimuli is faithfully detected by specific antibodies. Mol Cell Biol Res Commun 2000;3:205-11.
31. Cencic R, Robert F, Galicia-Vazquez G, Malina A, Ravindar K, Somaiah R, et al. Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A. Blood Cancer J 2013;3:e128.
32. Wang X, Flynn A, Waskiewicz AJ, Webb BL, Vries RG, Baines IA, et al. The phosphorylation of eukaryotic initiation factor eIF4E in response to phorbol esters, cell stresses, and cytokines is mediated by distinct MAP kinase pathways. J Biol Chem 1998;273:9373-7.
33. Lee KH, Nishimura S, Matsunaga S, Fusetani N, Horinouchi S, Yoshida M. Inhibition of protein synthesis and activation of stress-activated protein kinases by onnamide A and theopederin B, antitumor marine natural products. Cancer Sci 2005;96:357-64.
34. Bleumink M, Kohler R, Giaisi M, Proksch P, Krammer PH, Li-Weber M. Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression. Cell Death Differ 2011;18:362-70.